相关实验视频

Updated: May 20, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

在重症监护中实施和对基法林A的一年评估

Lukas Martin¹, Caren Martin¹, Arne Peine¹

¹Department of Intensive Care Medicine, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.

International journal of molecular sciences

|March 27, 2025

概括

基法林A 119-159 (PENK) 在重症监护室 (ICU) 的脏生物标志物中表现有前途. 与血清肌素相比,它可以更好地评估功能和预测替代疗法.

科学领域:

生物化学生物化学
腎臟病學 (nephrology) 是一種醫學專業.
关键护理医学关键护理医学

背景情况:

在ICU中急性损伤 (AKI) 诊断依赖于血清肌素 (sCr) 和尿液输出,这些都有局限性.
早期AKI诊断对于重症监护机构患者的治疗结果至关重要.

研究的目的:

在日常ICU实践中评估Proenkephalin A 119-159 (PENK) 作为功能性脏生物标志物.
将PENK的性能与sCr进行功能评估和AKI预测的比较.

主要方法:

在2020年11月至2022年3月期间,从4169名患者收集了PENK测量,sCr,AKI阶段和替代疗法 (RRT) 数据.
开发了PENK-GFR公式,以估计球膜过率.
分析了近18000个PENK测量的结果.

主要成果:

与sCr相比,PENK表现出优异的功能评估,包括随时间推移的轨迹.
PENK有效地预测了重症患者需要RRT的需求.
该PENK-GFR公式提供了一个估计的膜过率.

结论:

在重症监护中,PENK是评估功能的一个有价值的生物标志物.
PENK的预测能力提高了其在日常ICU实践中用于管理AKI的实用性.
通过更好的功能监测,PENK的实施支持改善患者护理.

关键词:

艾基 (AKI) 是一个人.这就是 PENK PENK PENK.关键护理关键护理关键护理功能生物标志物是功能生物标志物.脑蛋白 A 脑蛋白 A 是一种益恩基法林 A 1191599 是一种

更多相关视频

Real-Time Assessment of Spinal Cord Microperfusion in a Porcine Model of Ischemia/Reperfusion

Real-Time Assessment of Spinal Cord Microperfusion in a Porcine Model of Ischemia/Reperfusion

Published on: December 10, 2020

Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex

Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex

Published on: July 4, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...